Regulatory T Cells in Cancer

George Plitas1,2 and Alexander Y. Rudensky1,3

1Immunology Program and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; email: plitasg@mskcc.org, rudenska@mskcc.org
2Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
3Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Keywords
regulatory T cell, Treg suppression, cancer immunotherapy, tumor microenvironment, FOXP3, antitumor immune response, immune homeostasis

Abstract
The immune system has evolved complex effector mechanisms to protect the host against a diversity of pathogenic organisms and regulatory adaptations that can curtail pathological sequelae of inflammatory events, prevent autoimmunity, and assist in tissue repair. Cancers, by virtue of their local manifestations of tissue dysfunction and destruction, inflammation, and genomic instability, can evoke these protective mechanisms, which support the progression of tumors and prevent their immune eradication. Central to these processes is a subset of CD4+ T cells, known as regulatory T (Treg) cells, that express the X chromosome–linked transcription factor FOXP3. In addition to their critical role in controlling autoimmunity and suppressing inflammatory responses in diverse biological settings, Treg cells are ubiquitously present in the tumor microenvironment where they promote tumor development and progression by dampening antitumor immune responses. Furthermore, Treg cells can directly support the survival of transformed cells through the elaboration of growth factors and interacting with accessory cells in tumors such as fibroblasts and endothelial cells. Current insights into the biology of tumor-associated Treg cells have opened up opportunities for their selective targeting in cancer, with the goal of alleviating their suppression of antitumor immune responses while maintaining overall immune homeostasis.
INTRODUCTION

A large body of research suggests that the tumor and immune cell interactions can affect the development of cancer and aid in its control (Dunn et al. 2004). Clinically beneficial therapeutic modulation of the immune system in cancer patients has been demonstrated by numerous modalities, including antibody blockade of inhibitory molecules, adoptive T cell transfer, and autologous cell-based vaccines. Regulatory T (Treg) cells are a subset of CD4+ T cells that are requisite for control of autoimmunity, dampening excessive inflammation caused by the immune response to pathogens, and maintaining maternal-fetal tolerance (Josefowicz et al. 2012). While Treg cells are critical for maintaining peripheral tolerance, their potent immunoregulatory properties can promote the development and progression of numerous types of malignancies. Analysis of tumor-infiltrating lymphocyte (TIL) subsets has shown a clear association between the composition of the immune cell infiltrate and patient survival. TILs primarily composed of cytotoxic T cells are generally associated with a favorable prognosis, whereas an increased proportion of Treg cells among TILs is associated with poor outcomes (Fu et al. 2007, Petersen et al. 2006, Shen et al. 2010). Treg cells exert their suppressive function through several mechanisms (Josefowicz et al. 2012). CD25, a high-affinity binding subunit of the IL-2 receptor and the historical Treg cell surface marker, is constitutively and highly expressed on Treg cells but also upregulated on effector T cells (Fontenot et al. 2005). The high level of CD25 expression on Treg cells could deprive effector T cells of IL-2 and inhibit their proliferation (Chinen et al. 2016, Pandiyan et al. 2007). CTLA-4 (cytotoxic T lymphocyte antigen 4) is well known to limit responses of activated T cells and is also implicated in Treg cell–mediated suppression (Wing et al. 2008). Treg cells can produce multiple immunomodulatory proteins (see below) (von Boehmer 2005), are generally considered to be the most potent inhibitor of antitumor immunity, and are suspected to be responsible for the limited response rates to current immunotherapeutic regimens (Zou 2006). Treg cell differentiation and function are dependent on the expression of the lineage-specifying transcription factor FOXP3 (Rudensky 2011). Mice with a loss-of-function mutation in Foxp3 lack functional Treg cells and develop lethal autoimmunity and lymphoproliferative disease at an early age (Fontenot et al. 2003, Khattri et al. 2003). Similarly, humans harboring mutations in the FOXP3 gene suffer from immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX) manifested in widespread autoimmune and inflammatory lesions (Bennett et al. 2001). The emerging modalities of Treg cell–focused therapies are context specific; in inflammatory, allergic, and autoimmune diseases the goal is to augment Treg cell numbers and functional activity while inhibiting their suppressive mechanisms or depleting them in cancer. Strategies for developing immunotherapies that target Treg cells need to take into account that they are essential for immune homeostasis. Here, we provide an overview of Treg cell biology, discuss the features and roles of Treg cells in the tumor microenvironment (TME), and review the means by which they can be targeted for cancer immunotherapy.

REGULATORY T CELL PHENOTYPE AND FUNCTION

Over a century ago Paul Ehrlich first postulated the existence of regulatory mechanisms protecting against autoimmunity: “the organism possesses certain contrivances by means of which the immunity reaction, so easily produced by all kinds of cells, is prevented from acting against the organism’s own elements” (Ehrlich 1906, p. 253). Jacques Miller discovered that the thymus functions as the generation site of a major class of lymphocytes, T cells, and observed that thymectomy before day 3 of life unexpectedly results in a wasting disease (McIntire et al. 1964). Nishizuka & Sakakura (1969) further determined that the wasting disease in part was secondary to the autoimmune. Reversal of autoimmunity induced by neonatal thymectomy by the adoptive transfer of
thymocytes or splenocytes from adult mice led to the realization that a population of cells generated in the mouse thymus after 3 days of life mediates tolerance in a dominant cell-extrinsic manner (Sakaguchi 2004). The concept of a suppressive T cell subset was fortified with the landmark findings of Sakaguchi et al. (1995), who described a population of CD25-expressing CD4$^+$ T cells capable of suppressing autoimmune responses in several experimental models. Correlative in vitro studies in humans confirmed the existence of suppressive CD4$^+$CD25$^+$ T cells (Ng et al. 2001). With the increasing availability of tools for phenotyping T cell subsets, the existence of a suppressive T cell subset became established, and these cells were named “regulatory” or “Treg” cells. However, there was some lingering doubt as to whether Treg cells were a distinct T cell lineage, as their characteristic features—including increased expression of CD25, CTLA-4, and the TNF receptor family member GITR (glucocorticoid-induced TNF receptor)—were also found on activated conventional CD4$^+$ T (Tconv) cells. In an effort to identify a biologically important marker specific to Treg cells, researchers conducted an intense exploration of genetic mechanisms underlying the differentiation and function of Treg cells, which resulted in the identification of FOXP3, an X chromosome-encoded forkhead transcription factor family member (Fontenot et al. 2003, Hori et al. 2003, Khattri et al. 2003) whose high level of expression is characteristic of Treg cells in experimental animals and humans. Foxp3 was identified as the gene whose loss-of-function mutation in IPEX patients and in the spontaneously Scurfy-mutated mouse is responsible for fatal widespread early-onset autoimmunity (Bennett et al. 2001, Brunkow et al. 2001, Chatila et al. 2000, Wildin et al. 2001). While FOXP3 is also highly expressed in human CD25$^+$CD4$^+$ T cells that have a suppressor function, activated human Tconv cells also upregulate FOXP3, but only transiently and at a significantly lower level than the characteristically stable high–FOXP3 expression levels in Treg cells (Walker et al. 2003). Genetic cell fate mapping studies have shown a remarkable stability of differentiated Treg cells and a heritable maintenance of FOXP3 expression under physiologic and inflammatory conditions, strongly supporting the idea that Treg cells represent a dedicated lineage (Chen et al. 2003). A dedicated mechanism for Treg cell stability has been highlighted by the demonstration that an intronic Foxp3 cis-regulatory element CNS2 (conserved noncoding sequence 2) is essential for heritable maintenance of Treg cell identity during cell division when proinflammatory cytokines, promoting alternative cell fate, are present (Feng et al. 2014, Zheng et al. 2010). CNS2 [also known as TSDR (Treg cell–specific demethylated region)] contains a set of CpG residues that undergoes demethylation in fully differentiated Treg cells—a step essential for stable Foxp3 expression. Thus, CNS2 enforces the stability of the differentiated cell state in the Treg cell lineage in fluctuating environments, and this unique function of CNS2 is important in diverse chronic inflammation types including autoimmunity, chronic infection, metabolic inflammation, and cancer (Feng et al. 2014). Demethylation of CNS2 (TSDR) is presently viewed as a proxy for bona fide Treg cells with sustained functional capacity.

The neonatal thymectomy showed that the thymus is an essential source of Treg cells. The differentiation of thymic-generated Treg (tTreg) cells depends on high-avidity interactions with self-peptide/MHC class II complexes and IL-2 receptor signaling (Josefowicz & Rudensky 2009). Additionally, Treg cells could also be generated outside the thymus. These extrathymically generated or peripheral Treg (pTreg) cells develop from naive CD4$^+$ T cells upon exposure to antigenic stimulation under tolerogenic conditions. Specifically, strong TCR (T cell receptor) signaling, suboptimal costimulation, and high amounts of TGF-β and retinoic acid favor the induction of FOXP3 in peripheral naive CD4$^+$ T cells (Chen et al. 2003, Josefowicz et al. 2012). The differences between these Treg cell subsets suggest that tTreg cells are likely responsible for tolerance to self-antigens, whereas Treg cells restrain immune responses to so-called non-self-antigens including allergens, commensal microbiota, dietary antigens at barrier sites, and paternal alloantigens. The
Mechanisms of regulatory T (Treg) cell suppression. Treg cells engage multiple mechanisms by which they suppress immune responses and support the progression of cancer. Targets of suppression include innate and adaptive immune cells, elaboration of tumor growth factors such as the epithelial growth factor receptor (EGFR) ligand amphiregulin (Areg), and modulators of metabolism.

Relative contributions of tTreg and pTreg cells to progression to different cancer types remain to be established.

The suppressor function of Treg cells is essential for restraint of fatal autoimmune and inflammatory responses throughout the lifespan of an organism (Kim et al. 2007). Transcriptional profiling and flow cytometric analyses of Treg cells have revealed several candidate molecules that could potentially mediate suppression (Figure 1). These include CD39 ecto-nucleotidase, which is highly expressed on both human and mouse Treg cells. The latter cells also express high amounts of CD73. This pair of ecto-enzymes facilitates the conversion of extracellular ATP, which has a potent proinflammatory activity, to adenosine, which by acting through A2A receptor inhibits the proliferation of effector T cells and the activation of dendritic and myeloid cells. Treg cells also produce several secreted immunomodulatory proteins including IL-10, granzymes, and TGF-β (tumor growth factor β) (Vignali et al. 2008). IL-10 production by Treg cells is essential for keeping the immune response in check at environmental interfaces such as the colon, lungs, and likely in the TME (Rubtsov et al. 2008, Sawant et al. 2019). Furthermore, high levels of CTLA-4 expression by Treg cells may enable them to suppress costimulatory capacity of dendritic cells by restraining CD80 and CD86 expression (Wing et al. 2008). Congenital CTLA-4 deficiency limited to Treg cells is associated with a lymphoproliferative disorder. However, conditional ablation of CTLA-4 in differentiated Treg cells in adult mice does not precipitate systemic autoimmunity, suggesting the existence of compensatory regulatory mechanisms independent of CTLA-4 or a role of CTLA-4 in Treg cell differentiation (Paterson et al. 2015). Finally, IL-2 consumption by Treg cells is essential for control of CD8+ T cell responses but is dispensable for control of CD4+ T cell activation and expansion (Chinen et al. 2016). TCR and IL-2 receptor signaling are required for the suppressor activity of Treg cells (Chinen et al. 2016, Levine et al. 2014). However, Treg cells employ multiple mechanisms of suppression and no single mechanism can account for the entire spectrum of their suppressor function.

REGULATORY T CELLS IN CANCER

An increased frequency of Treg cells in the TME is associated with an adverse prognosis in several cancer types (Fu et al. 2007, Petersen et al. 2006, Shen et al. 2010). One notable exception is colorectal cancer, where Treg cells may suppress tumor-promoting inflammatory responses elicited by the gut microbiota (Saito et al. 2016). The frequency of Treg cells may also have implications...
Recruitment and maintenance of Treg cells in the tumor microenvironment. Multiple factors contribute to the increased frequency of Treg cells in tumors over normal tissues. Treg cells express specific chemokine receptors whose ligands are produced by various cells in the tumor microenvironment. Several mechanisms exist that contribute to the survival, stability, and proliferation of Treg cells in tumors, including conversion from CD4+ T cells, metabolic adaptation, and stability of FOXP3 expression. Neoantigen and self-antigen reactivity may also contribute to the prevalence of Treg cells in neoplastic tissues. Abbreviations: MHC II, major histocompatibility complex class II; NK, natural killer; TCR, T cell receptor; T\text{eff}, effector T cell; Treg, regulatory T.

for predicting response to immunotherapy. Higher pretreatment levels of circulating Treg cells were associated with improved survival in melanoma patients treated with ipilimumab (Martens et al. 2016). Similarly, in non-small-cell lung cancer patients, a positive correlation has been observed between response to PD-1/PD-L1 blockade and the frequency of PD-L1+ Treg cells in the TME (Wu et al. 2018). Treg cells can suppress antitumor immune responses using several different mechanisms (Figure 2). The high level of expression of IL-2Ra chain could deprive local environments of IL-2 and negatively impact effector T cell function and expansion (Pandiyan et al. 2007). The modulation of IL-2 levels by Treg cells also has important consequences for NK (natural killer) cell homeostasis and function (Gasteiger et al. 2013). Treg cells also regulate antigen-presenting cells as noted above, with a pronounced dendritic cell expansion and activation acutely upon Treg cell depletion (Kim et al. 2007). This suppression may in part be due to CTLA-4-dependent downregulation of CD80 and CD86 expression by a process termed trans-endocytosis (Qureshi et al. 2011). Cytolysis of target cells as a means for Treg cell–mediated suppression was first suggested by the finding that, in human Treg cells, granzyme A can be induced by a combination of CD3 and CD46 stimulation, resulting in the induction of apoptosis in
activated target cells (Grossman et al. 2004). In mice, granzyme B and perforin produced by Treg cells can lead to NK and CD8+ T cell death and suppression of tumor clearance (Cao et al. 2007). CD39 and CD73 highly expressed on Treg cells can affect the TME, with its prevalent necrotic cell death associated with the release of ATP, by facilitating the conversion of ATP, the elaboration of adenosine, and the extrusion of cAMP (Deaglio et al. 2007). Adenosine signaling initiated by Treg cells not only directly inhibits the proliferation of effector T cells but also negatively regulates dendritic cells. Additionally, a high level of Treg cell surface expression of an MHC class II binding inhibitory receptor LAG-3, homologous to CD4, may facilitate the ability of Treg cells to suppress activation of dendritic cells (Liang et al. 2008).

Treg cells in tumors display a highly activated phenotype with high levels of CD45RO and correspondingly low levels of CD45RA, as well as strong expression of costimulatory (GITR, ICOS, OX40) and coinhibitory (CTLA-4, PD-1, LAG3) molecules (Azizi et al. 2018, De Simone et al. 2016, Plitas et al. 2016). The covariance of expression of these molecules contributes to the phenotypic heterogeneity of Treg cells in tumors (Azizi et al. 2018). The observed increased frequency of Treg cells among TILs is likely secondary to several factors. Several lines of evidence point to recruitment of Treg cells through chemokine-dependent migratory cues as a means of their accumulation in the TME. Chemokines are a superfamily of chemotactic secreted proteins that control leukocyte migration through G protein–coupled receptors on target cells, and they play a role both in the recruitment of immune and inflammatory cells for antitumor response and of immunomodulatory cells, including Treg cells, and in the selective homing of neoplastic B and T cells (Nagarsheth et al. 2017). For example, Treg cells can be recruited to squamous cell carcinomas and colorectal cancer tumors in a CCR5-dependent manner (Ward et al. 2015). Hypoxia-driven secretion of CCL28 from hepatocellular carcinoma cells promoted recruitment of Treg cells into liver tumors, which then promoted in turn angiogenesis through VEGF expression (Ren et al. 2016). The chemokine receptor CCR4, highly expressed by Treg cells, has been implicated in their trafficking to several nonlymphoid organs and tumors, and it has been suggested that Treg cell migration into the tumor can be inhibited through CCR4 blockade (Colombo & Piconese 2007). Another chemokine receptor, CCR8, has also been identified as preferentially expressed on tumor-resident Treg cells that exhibit chemotaxis to the CCR8 ligand CCL1 (De Simone et al. 2016, Plitas et al. 2016). CCR8 expression can be selectively induced on CCR8 Treg cells by a yet unknown soluble factor from the TME (Plitas et al. 2016).

The similarities between tumor- and normal tissue–resident Treg cells may seem to indicate that the origins of intratumoral Treg cell populations derive from their normal tissue counterparts rather than recruitment from the circulation (Plitas et al. 2016). On a functional side, the tissue repair function of normal lung–resident Treg cells in mice is recapitulated by Treg cells from lung tumors (Arpaia et al. 2015, Green et al. 2017). Lung-resident Treg cells produce the EGFR ligand amphiregulin, which promotes normal and malignant epithelial cell growth and may act on other cells both in normal lung and in the TME. However, it is much more likely that these observations reflect imprinting of the overall similar features by normal tissue and the TME and that the observed differences can be accounted for by varying the availability of oxygen and metabolites, as well as Treg cell activation. In addition, when comparing the T cell receptor repertoire of Treg cells from normal breast tissue and breast cancers in matched patients, researchers have found little overlap, suggesting that the local expansion of tissue-resident Treg cells is unlikely the origin of intratumoral Treg cells, which is consistent with the notion above that the TME imprints Treg cells with unique phenotypic and functional properties (Plitas et al. 2016). Another means by which Treg cells may accumulate in the TME is through the conversion of Tconv cells upon TCR stimulation in the presence of TGF-β in a manner dependent on the aforementioned CNS1 enhancer (Zheng et al. 2010). Immunosuppressive factors in the TME including TGF-β,
IL-10, and VEGF can promote the differentiation of pTreg cells, facilitated by tolerogenic antigen–presenting cells (Zhou & Levitsky 2007). Indoleamine 2,3-dioxygenase (IDO)-expressing APCs may promote the conversion of Treg cells through an aryl hydrocarbon receptor (Curti et al. 2007). It would be expected that if the major source of intratumoral Treg cells is from conversion of Tconv cells, there would be considerable overlap in the T cell receptor repertoire between clonally expanded effector and Treg cells. This, however, has not been observed in the human breast cancers where very limited overlap was observed between Treg and Tconv cells isolated from tumors, comparable to that between Treg and Tconv cells in normal breast tissue obtained from the same patient through contralateral mastectomy (Plitas et al. 2016). These findings have also been recapitulated in human melanoma samples where the TCR repertoires of intratumoral Treg cells displayed significant overlap with peripheral blood Treg cells but not with Tconv cells in tumor or blood (Ahmadzadeh et al. 2019). Interestingly, TCRs isolated from tumor-resident Treg cells can display reactivity against mutated neoantigens, suggesting activation and clonal expansion in the TME (Ahmadzadeh et al. 2019). Treg cells specific for the cancer-testes antigen NY-ESO-1 can be found in the peripheral blood of patients with melanoma, and their abundance correlates with an adverse prognosis (Vence et al. 2007). In patients with colorectal cancer, tumor antigen–specific Treg cells can be readily identified, and their depletion leads to an increase in effector T cell responses against the same antigens (Bonertz et al. 2009).

**METABOLIC ADAPTATIONS OF REGULATORY T CELLS IN THE TUMOR MICROENVIRONMENT**

Nutrient and metabolic signals modulate T cell differentiation and function (Pearce et al. 2013). TCR engagement leads to a specific metabolic program mediated by signaling through the PI3K-mTOR pathway, leading to increased amino acid and glucose uptake to fuel aerobic glycolysis. The balance of metabolic pathways can modulate the fate of T cell differentiation. For example, the relative degree to which glycolysis or fatty acid oxidation is utilized by an uncommitted precursor cell can strongly impact its Th17 (T helper 17) and Treg differentiation through differential activity of mTOR, HIF-1α, and PPAR-γ, which in turn can modulate the expression of the corresponding lineage-restricted factors RORγt and FOXP3 (Berod et al. 2014, Klotz et al. 2009). The TME supports the bioenergetic needs of cancer cells reliant on aerobic glycolysis, fatty acid synthesis, and glutaminolysis (Hanahan & Weinberg 2011). This nutrient-poor, lactate-rich, hypoxic, and acidic environment poses a considerable restraint on effector T cells, which rely primarily on glycolysis (Buck et al. 2017). To the contrary, Treg cells may have a metabolic advantage in this environment by utilizing alternative substrates and metabolic pathways for energy production, such as fatty acid oxidation and oxidative phosphorylation. FOXP3 orchestrates this distinct metabolic program by suppressing glycolysis, leading to enhanced oxidative phosphorylation and increasing nicotinamide adenine dinucleotide oxidation, potentially allowing Treg cells to resist lactate-mediated suppression of T cell function in the TME while also enabling Treg cells’ use of lactate as a fuel source (Angelin et al. 2017, Fischer et al. 2007). In addition to lactate, fatty acids generated in the TME by transformed cells or tumor-associated stromal cells (Hoy et al. 2017, Rohrig & Schulze 2016) can inhibit effector T cells, while promoting the progression of carcinomas (Kleinfeld & Okada 2005, Lochner et al. 2015, Ma et al. 2016). Treg cells engage multiple mechanisms that allow for their adaptation to the increased presence of fatty acids. Tumor-resident Treg cells in murine models of cancer display intracellular lipid accumulation attributable to an increased rate of fatty acid synthesis, and Treg cells from human breast cancers engage a transcriptional program supporting lipid synthesis (Pacella et al. 2018). Furthermore, oxidative metabolism of lipids by Treg cells not only decreases their demand for glucose but also confers resistance to...
fatty acid–induced cell toxicities (Howie et al. 2017). Metabolic competition between Treg cells and effector cells has also been proposed to lead to senescence in effector T cells as mediated by ATM-associated DNA damage, which can be reversed by TLR8 signaling (Liu et al. 2018). The decreased concentrations of glutamine in the TME may also contribute to the increased frequency of Treg cells, as glutamine deprivation has been suggested to promote FOXP3 expression. Specifically, the loss of glutamine-dependent α-ketoglutarate production and a decreased UDP-GlcNAc synthesis in T cells have been shown to favor the differentiation of pTreg cells (Araujo et al. 2017, Klysz et al. 2015). However, the degree to which pTreg cell differentiation contributes to the overall Treg cell pool in different types of cancers remains to be investigated.

Apart from adapting to the unique metabolic constraints of the TME, Treg cells can directly shape it. For example, the aforementioned Treg cell expression of CD39, acting along with C73 expressed by chronically stimulated intratumoral CD8+ T cells and other cell types, promotes the conversion of ATP to adenosine (Maj et al. 2017). Since extracellular ATP is immunostimulatory and adenosine is immnosuppressive (Antonioli et al. 2013), therapeutic targeting of this pathway can promote antitumor immune responses and synergize with checkpoint inhibitors (Willingham et al. 2018). The increased local catabolism of tryptophan by IDO can also contribute to attenuated antitumor immunity in part through activation of Treg cells in the TME. Tumor cell expression of IDO correlates with an increased frequency of Treg cells in the TME (Godin-Ethier et al. 2011). IDO can also inhibit the reprogramming of Treg cells into Th17 cells by reducing IL-6 production by dendritic cells (Chai 2011). The PI3K-Akt-mTOR pathway is an important regulator of Treg cells’ stability and function in the TME, leading to inhibition of suppressive function and reprogramming into effector-like cells in the setting of TCR activation (Munn & Mellor 2016; Sharma et al. 2009, 2015). IDO activity can help to preserve the stability of Treg cells in the TME by opposing the mTORC2-Akt pathway (Sharma et al. 2015). Kynurenine, a tryptophan metabolite, can increase the suppressive activity of Treg cells and promote their expansion by acting as an endogenous ligand of the aryl hydrocarbon receptor (Baban et al. 2009, Fallarino et al. 2006). It is becoming increasingly clear that the distinct metabolic programs of, and competition for metabolites between, tumors and different immune cell subsets in the TME have a significant impact on antitumor immunity and represent a promising space for therapeutic intervention.

REGULATORY T CELL–BASED THERAPEUTIC INTERVENTIONS

Studies in preclinical cancer models in mice strongly indicate that Treg cell depletion can induce strikingly effective antitumor immune responses (Bos et al. 2013, Green et al. 2017, Onda et al. 2019). The major issues with a depletion strategy have been that potential molecular targets are shared between Treg cells and effector cells, as well as the potential for devastating autoimmune toxicities that may result from an indiscriminate Treg cell depletion. Preclinical and clinical findings form the basis of current efforts to develop effective Treg cell targeting methods, including transient generalized depletion, local depletion, or inactivation of intratumoral Treg cells. Thus, advances in the understanding of basic principles of Treg cell biology are beginning to translate into clinical practice.

CD25

CD25 has been a recurring focus of strategies to therapeutically target Treg cells due to both its very high expression on Treg cells and IL-2 being a critical factor of Treg cell differentiation, maintenance, and function. The concern regarding immune-related toxicities has been of continued relevance in this line of research, as blocking IL-2 or CD25 in mice resulted in various manifestations of autoimmunity (Chinen et al. 2016, McHugh & Shevach 2002, Setoguchi
et al. 2005). Depending on the Fc receptor interaction of CD25-specific antibodies, CD25 can be blocked or used to deplete Treg cells, with very different systemic immune consequences (Huss et al. 2016). Initial attempts at Fc receptor–mediated depletion did demonstrate induction of antitumor immune responses; however, also evident were manifestations of autoimmunity (Shimizu et al. 1999). This strategy was translated to the clinic in trials of the anti-CD25 antibody dacluzimab, which were largely unsuccessful likely due to the propensity of dacluzimab to deplete Treg- and CD25-expressing effector cells (Jacobs et al. 2010, Rech et al. 2012). Recent work, however, suggests that conventional anti-CD25 antibodies did not effectively deplete Treg cells in the TME potentially due to the upregulation of the inhibitory Fc gamma receptor at the tumor site; engineering the antibodies to selectively bind activating Fc gamma receptors may be more efficacious (Arce Vargas et al. 2017). An alternative strategy of targeting IL-2R-expressing cells including Treg cells relies on the use of a recombinant IL-2 diphtheria toxin fusion protein, also known as ONTAK. Like Treg cells expressing high levels of CD25, ONTAK was efficacious for the treatment of cutaneous T cell lymphoma and its administration was also shown to significantly decrease Treg cells in peripheral blood (Mahnke et al. 2007, Olsen et al. 2001). However, further development was hampered by production issues and a major dose-limiting toxicity due to vascular leak syndrome, leading to the recent engineering of a second-generation agent (Cheung et al. 2019).

Cosignaling Molecules

Cosignaling molecules expressed by immune cells can be divided functionally into costimulatory (e.g., CD28, ICOS, TNFR2, OX40, and 4-1BB) and coinhibitory (e.g., CTLA-4, PD-1 TIM3, LAG3, and TIGIT) receptors. The differential expression and activity of these molecules directs immune responses in a context-dependent fashion by promoting activation and differentiation of T cells while providing negative feedback and affording fine-tuned immunoregulation. While conventional (effector) T cells generally require antigen exposure and subsequent activation to upregulate cosignaling molecules, many of them are constitutively expressed by Treg cells (CTLA-4, OX40, GITR, etc.)—likely owing to heightened TCR signaling required for their generation—and are important to their differentiation, survival, and suppressive activities. High cell surface expression of some such molecules, including PD-1, ICOS, TIGIT, LAG3, TIM3, TNFR2, and 4-1BB, can be viewed as rationale for antibody development for potential Treg-specific targeting (Anderson et al. 2016, Bour-Jordan & Bluestone 2009).

In addition to being highly expressed on and functionally important for Treg cells, CTLA-4 affords an essential cell-intrinsic negative feedback mechanism of effector T cell responses (Paterson et al. 2015). Ipilimumab, an IgG1 anti-CTLA-4 antibody, has been clinically validated as an effective immunotherapeutic agent (Robert et al. 2011). The mechanism of action of anti-CTLA-4 antibodies in preclinical tumor models is dependent on both Treg cell depletion and effector T cell activation (Peggs et al. 2009). Utilizing depleting rather than neutralizing CTLA-4 antibodies as a means of targeting Treg cells may have a greater impact, as Treg cells from CTLA-4-knockout mice are still capable of mediating immune suppression (Lutsiak et al. 2005). In humans, it is not clear if the predominant mechanism underlying therapeutic efficacy of CTLA-4 antibodies is Treg cell depletion or the expansion and activation of effector cells directly. While some analyses of clinical samples suggest that ipilimumab can deplete intratumoral Treg cells (Romano et al. 2015, Tarhini et al. 2014), other studies failed to observe it (Ferrara et al. 2018). In this regard, tremelimumab, an IgG2 isotype CTLA-4 antibody with minimal potential antibody-dependent cytotoxicity, appears to have similar clinical activity as ipilimumab, suggesting that Treg depletion is not a critical mechanism by which CTLA-4 antibodies work (Ferrara et al. 2018). The degree to which CTLA-4 antibodies deplete Treg cells in tumors and the contribution of this effect to
their overall therapeutic efficacy are likely influenced by host Fc receptor polymorphisms and the availability of effectors of antibody-dependent cellular cytotoxicity in the TME (Arce Vargas et al. 2018). There is current considerable interest in engineering CTLA-4 antibodies with enhanced Fc receptor activity to deplete Treg cells. However, there is the issue of concomitantly depleting activated effector cells, and it may be beneficial to incorporate this understanding in sequencing therapeutic modalities with vaccination strategies or other immunostimulatory strategies (Ha et al. 2019). Similar to CTLA-4, PD-1 is also highly expressed by tumor-resident Treg cells. Targeting the PD-1/PD-L1 pathway is the most effective of current immunotherapies, and anti-PD-1/PD-L1 antibodies are thought to mediate their effect by maintaining the phosphorylated state of Shp2 phosphatases downstream of CD28 costimulatory signals, leading to T cell activation (Dong et al. 2002, Hui et al. 2017, Iwai et al. 2002, Nishimura et al. 1999). Interestingly, loss of PD-1 expression on Treg cells also leads to enhanced suppressive function, which may appear counterintuitive considering the clinical activity of PD-1/PD-L1 blockade (Sage et al. 2013). However, this observation raises the possibility that the activity of Treg cells during PD-1-based therapies may limit effectiveness, and combination interventions targeting Treg cells along with PD-1 warrant investigation.

The TNFα (tumor necrosis factor alpha) superfamily is composed of more than 40 members and is associated with a similar number of membrane or soluble receptors (TNFR). Costimulation through the TNFR superfamily is critically important in Treg cell differentiation and functionality (Mahmud et al. 2014). GITR, a member of the TNFR superfamily constitutively expressed on Treg cells, can also be induced upon activation of effector CD4+ and CD8+ T cells (Schaer et al. 2012). GITR activation leads to effector T cell activation and inhibition of Treg cell activity in tumors (Aida et al. 2014, Ko et al. 2005). Agonistic GITR antibodies have shown antitumor activity in numerous preclinical models both alone and in combination with other immunotherapies (Kim et al. 2015, Leyland et al. 2017). The mechanisms underlying these responses are thought to be largely related to a reduction in the number of intratumoral Treg cells and a concomitant increase in effectors (Cohen et al. 2010). The mechanism by which agonistic GITR antibodies reduces the frequency of Treg cells in tumors is likely secondary to depletion of a relatively activated subset of Treg cells (Mahne et al. 2017). Several GITR agonists are currently in early-phase clinical trials, with two early reports that suggest that they have antitumor activity in combination with a PD-1 antibody but no such activity as monotherapy (Pacella et al. 2018, Siu et al. 2017). OX40 is expressed on several TIL subsets including Treg cells in multiple cancer types (Aspeslagh et al. 2016). Tumor-resident Treg cells preferentially express high levels of OX40, and intratumoral delivery of anti-OX40 antibodies in mice leads to Treg cell depletion, which can be synergistic with other local immunotherapeutic approaches (Marabelle et al. 2013, Piconese et al. 2008). However, these observations are in contrast to what has been observed in human clinical trials, where there was no significant depletion of Treg cells but there was an increase in the proliferation of effector cells and some clinical responses (Curti et al. 2013). Combination therapies are also being investigated clinically; however, the preclinical data are cautionary, as combining OX40 agonism with concurrent PD-1 blockade resulted in a less-effective therapy than OX40 agonism alone (Shrimali et al. 2017). RANKL is another member of the TNF-α superfamily (TNFSF11) and binds to a membrane receptor named RANK (receptor activator of nuclear factor-κB), a member of the TNFR superfamily (TNFRSF11A) (Ahern et al. 2018). RANK and RANKL are commonly expressed in the TME and can impact the antitumor immune response (Chu & Chung 2014). RANK-expressing tumor-associated macrophages potentiate Treg cell proliferation and expression of RANKL, which can potenti ate breast cancer metastases (Gonzalez-Suarez et al. 2010, Li et al. 2010, Tan et al. 2011). This feedback loop can be therapeutically targeted by RANKL blockade in association with Treg cell depletion (Ahern et al. 2017). TNF binds to two distinct
receptors: TNFR1, which is ubiquitously expressed, and TNFR2, which is predominantly expressed by Treg cells, a subset of neural cells, and endothelial cells (Kalliolas & Ivashkiv 2016). TNFR2 signaling can expand Treg cells, which may be protective against graft-versus-host disease (Chopra et al. 2016). Similarly, antibodies antagonizing the function of TNFR2 inhibit the proliferation of Treg cells and may be an effective immunotherapy (Torrey et al. 2017).

Chemokine Receptors

Differential gene expression analyses have revealed that tumor-resident Treg cells may have a distinct expression pattern of chemokine receptors that may be exploited for therapeutic purposes (De Simone et al. 2016, Plitas et al. 2016). CCR4, which is highly expressed on Treg cells and other CD4+ T cell subsets, is important for Treg cell migration, and accordingly, its ligands are expressed by various cells in the TME (Curiel et al. 2004, Faget et al. 2011). This interaction has been the focus of numerous therapeutic strategies. A small-molecule inhibitor of CCR4 designed in silico has been shown to prevent the interaction of CCL22 and CCL17 with CCR4 and consequently inhibit the recruitment of Treg cells in experimental models (Davies et al. 2009). Further work with this molecule showed that CCR4 antagonism could enhance dendritic cell-mediated CD4+ T cell proliferation in vitro, as well as offer potent adjuvant activity in an in vivo viral infection model (Bayry et al. 2008). Similarly, in tumor models, CCR4 antagonism induced expansion of antigen-specific CD8+ T cells and, in combination with vaccination, promoted tumor immunity (Pere et al. 2011). Treg cell depletion using mogamulizumab, a depleting (defucosylated to enhance cytotoxicity) CCR4 antibody, may augment antitumor immune responses, yet no significant clinical responses have been reported so far in current clinical trials. The latter can be due to depletion of several T cell subsets other than Treg cells, raising the concern that these populations may be important effector cells (Kurose et al. 2015). Further comparisons of Treg cells from malignant and normal tissues have revealed CCR8 to be a marker for tumor-resident Treg cells with greater specificity and displaying a considerably more restricted expression pattern than CCR4 (De Simone et al. 2016, Magnuson et al. 2018, Plitas et al. 2016). CCR8-deficient mice have a normal lifespan and do not develop spontaneous disease, suggesting that targeting CCR8 as a cancer immunotherapy may have a safer toxicity profile than molecules that are central to immune homeostasis such as CTLA-4 and IL-2 (Chensue et al. 2001). A murine model of colon cancer targeting CCR8 with an antibody led to reduced tumor growth, suggesting that targeting Treg cells via CCR8 may be efficacious (Villarruel et al. 2018).

Conventional Cytotoxic Agents

It has been repeatedly observed that conventional therapies that target malignant tumors are associated with enhanced antitumor immunity. One of the earliest examples is the association of low-dose cyclophosphamide, a chemotherapeutic agent, with enhanced immune responses (Rollinghoff et al. 1977). This effect was linked to the depletion of suppressor cells, which were eventually identified as Treg cells (Ghiringhelli et al. 2004). More detailed analyses revealed that low-dose cyclophosphamide can not only deplete Treg cells but also inhibit their functionality. The mechanism may in part be secondary to the increased proliferative state of the Treg cell population, rendering these cells susceptible to alkylating agents, and to the lack of the transporter necessary for extruding intracellular cyclophosphamide (Dimeloe et al. 2014). Interestingly, the impact of cyclophosphamide on Treg cells is not unique and has been observed with other chemotherapeutic agents (Galluzzi et al. 2012). Clinically, this effect has been utilized in many trials looking to increase the immunogenicity of therapeutic interventions by concomitantly depleting Treg cells with low-dose cyclophosphamide. Some encouraging associations have
been made between outcomes of patients with colorectal cancer treated with a vaccine-plus-cyclophosphamide combination and the degree of Treg cell depletion in the peripheral blood (Scurr et al. 2017). However, in larger trials the addition of cyclophosphamide did not improve outcomes (Rini et al. 2016). The observed discrepancies may be due to the depletion of effector cells or the induction of other suppressive immune cell subsets such as myeloid-derived suppressor cells (Sevko et al. 2013). Further research will hopefully elucidate if there will be a role for chemotherapy as an immunomodulatory agent in the treatment of cancer. Radiotherapy is also a commonly used cytotoxic modality through the induction of DNA damage and free radical formation. Radiation can lead to antitumor immune responses, which also can contribute to its therapeutic effectiveness (Demaria & Formenti 2013). Radiotherapy likely contributes to the activation of innate immune and tissue damage sensors and to antigen release from dying cancer cells, leading to enhanced antigen presentation by dendritic cells, while reducing the tumor mass and, therefore, the chances of tolerance induction in newly recruited effector T cells (Formenti & Demaria 2009). Thus, the adjuvant-type of immunological effects of radiotherapy may synergize with immunotherapy (Formenti et al. 2018). However, there are also known immunosuppressive effects of radiotherapy with an increase in the frequency of Treg cells featuring prominently in stereotactically irradiated tumors (Muroyama et al. 2017). This is likely secondary to the known relative radiation resistance of Treg cells (Komatsu & Hori 2007). Targeting Treg cells has been shown to markedly improve the therapeutic efficacy of radiotherapy and warrants further clinical investigation (Bos et al. 2013).

CONCLUDING REMARKS

Tumor growth requires the mutual adaptation of cancerous cells and surrounding accessory cells, encompassing cells of both the adaptive and innate immune systems. These adaptations include shaping of the cellular and molecular features of genetically unstable tumors by the host immune system. Central to these adaptive mechanisms is the recruitment of Treg cells, whose potent suppressive capabilities inhibit effector T cells, confer tumor-growth-promoting properties on myeloid cells, and may directly support the survival of tumor cells. Treg cell depletion has a profound therapeutic effect in animal cancer models, the clinical translation of which is hampered by the absolute necessity of Treg cells for maintaining immune homeostasis. Insights into the biology of Treg cells have revealed context-specific functions, which have led to several studies of the phenotype and function of tumor-resident Treg cells. These advances are paving the way for rational and theoretically safer targeting of tumor-specific Treg cells and are beginning to translate into clinical practice.

DISCLOSURE STATEMENT

The authors have submitted a patent application describing the use of CCR8 antibodies to deplete Treg cells. G.P. has consulting support from Merck and Tizona Therapeutics. A.Y.R. is an advisor to and holds stock options from FLX Bio, Surface Oncology, Vedanta Biosciences, and IFM Therapeutics; is an advisor to BioInvent International; and is a consultant to Omeros.

ACKNOWLEDGMENTS

This study was supported by NIH (National Institutes of Health) grant R37 AI034206 (to A.Y.R), Cancer Center Support Grant P30 CA008748, the Ludwig Center at Memorial Sloan Kettering, and the Hilton-Ludwig Cancer Prevention Initiative. G.P. is the recipient of a Breast Cancer
Alliance Young Investigator Grant and an American Surgical Association Foundation Fellowship. A.Y.R. is an investigator with the Howard Hughes Medical Institute.

LITERATURE CITED

Ahern E, Harjunpaa H, Barkauskas D, Allen S, Takeda K, et al. 2017. Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice. Clin. Cancer Res. 23:5789–801

Ahern E, Smyth MJ, Dougall WC, Teng MWL. 2018. Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy. Nat. Rev. Clin. Oncol. 15:676–93

Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanovic S, et al. 2019. Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci. Immunol. 4:eaaoo4310

Aida K, Miyakawa R, Suzuki K, Narumi K, Udagawa T, et al. 2014. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Cancer Sci. 105:159–67

Anderson AC, Joller N, Kuchroo VK. 2016. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989–1004

Angelini A, Gil-de-Gomez L, Daiya S, Jiao J, Guo L, et al. 2017. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25:1282–93.e7

Antonioli L, Blandizzi C, Pacher P, Hasko G. 2013. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13:842–57

Araujo L, Khim P, Mkhikian H, Mortales CL, Demetriou M. 2017. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. eLife 6:e21330

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, et al. 2018. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33:649–63.e4

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, et al. 2017. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46:577–86

Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, et al. 2015. A distinct function of regulatory T cells in tissue protection. Cell 162:1078–89

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. 2016. Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer 52:50–66

Azizi E, Carr AJ, Pilitas G, Cornish AE, Konopacki C, et al. 2018. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174:308.e36

Baban B, Chandler PR, Sharma MD, Pikhala J, Koni PA, et al. 2009. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183:2475–83

Bayry J, Tihlilian EZ, Davies MN, Forbes EK, Draper SJ, et al. 2008. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. PNAS 105:10221–26

Bennett CL, Christie J, Ramsdell F, Brunek ME, Ferguson PJ, et al. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27:20–21

Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, et al. 2014. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 20:1327–33

Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, et al. 2009. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Investig. 119:3311–21

Bos PD, Pilitas G, Rudra D, Lee SY, Rudensky AY. 2013. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210:2435–66

Bour-Jordan H, Bluestone JA. 2009. Regulating the regulators: Costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229:41–66
Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27:68–73

Buck MD, Sowell RT, Kaech SM, Pearce EL. 2017. Metabolic instruction of immunity. Cell 169:570–86

Cao X, Cai SF, Fehninger TA, Song J, Collins LI, et al. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27:635–46

Chai JG. 2011. Cancer vaccination reprograms regulatory T cells into helper CD4 T cells to promote antitumor CD8 T-cell responses. Immunotherapy 3:601–4

Chatila TA, Blaser F, Ho N, Lederman HM, Voulgaropoulos C, et al. 2000. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic deregulation syndrome. J. Clin. Investig. 106:R75–81

Chen W, Jin W, Hardegen N, Lederman HM, Voulgaropoulos C, et al. 2003. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198:1875–86

Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, et al. 2001. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J. Exp. Med. 193:573–84

Cheung LS, Fu J, Kumar P, Kumar A, Urbanowski ME, et al. 2019. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergies with anti-PD-1 in melanoma. PNAS 116:3100–5

Chinen T, Kannan AK, Levine AG, Fan X, Klein U, et al. 2016. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17:1322–33

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, et al. 2016. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J. Exp. Med. 213:1881–900

Chu GC, Chang LW. 2014. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 33:497–509

Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, et al. 2010. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLOS ONE 5:e10436

Colombo MP, Piconese S. 2007. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7:880–87

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942–49

Curti A, Pandolfo S, Valzasina B, Alugi M, Isidori A, et al. 2007. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells. Blood 109:2871–77

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, et al. 2013. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73:7189–98

Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, et al. 2009. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLOS ONE 4:e8084

De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, et al. 2016. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45:1135–47

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204:1257–65

Demaria S, Formenti SC. 2013. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front. Oncol. 3:312

Demeloe S, Frick C, Fischer M, Gulser PM, Razik L, et al. 2014. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur. J. Immunol. 44:3614–20

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793–800
Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 21:137–48

Ehrlich P. 1906. *The Collected Papers of Paul Ehrlich*, Vol. 2, *Immunology and Cancer Research*, ed. F Himmelweit. New York: Pergamon

Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, et al. 2011. Early detection of tumor cells by innate immune cells leads to $T_{reg}$ recruitment through CCL22 production by tumor cells. *Cancer Res.* 71:6143–52

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate $T$ cell receptor $\zeta$-chain and induce a regulatory phenotype in naive T cells. *J. Immunol.* 176:6752–61

Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, et al. 2014. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. *Cell* 1158(4):749–63

Ferrara R, Susini S, Marabelle A. 2018. Anti-CTLA-4 immunotherapy does not deplete FOXP3$^+$ regulatory T cells (Tregs) in human cancers—letter. *Clin. Cancer Res.* 25:3468

Fischer K, Hoffmann P, Voellk S, Meidenbauer N, Ammer J, et al. 2007. Inhibitory effect of tumor cell-derived lactic acid on human T cells. *Blood* 109:3812–19

Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4$^+$ CD25$^+$ regulatory T cells. *Nat. Immunol.* 4:330–36

Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat. Immunol.* 6:1142–51

Formenti SC, Demaria S. 2009. Systemic effects of local radiotherapy. *Lancet Oncol.* 10:718–26

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, et al. 2018. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. *Nat. Med.* 24:1845–51

Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. 2007. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. *Gastroenterology* 132:2328–39

Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. 2012. The secret ally: immunostimulation by anticancer drugs. *Nat. Rev. Drug Discov.* 11:215–33

Gasteiger G, Hemmers S, Firth MA, Le Floc’h A, Huse M, et al. 2013. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. *J. Exp. Med.* 210:1167–78

Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, et al. 2004. CD4$^+$ CD25$^+$ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. *Eur. J. Immunol.* 34:336–44

Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. 2011. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. *Clin. Cancer Res.* 17:6985–91

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, et al. 2010. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. *Nature* 468:103–7

Green JA, Arpaia N, Schizas M, Dobrin A, Rudensky AY. 2017. A nonimmune function of T cells in promoting lung tumor progression. *J. Exp. Med.* 214:3365–75

Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. 2004. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity* 21:589–601

Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, et al. 2019. Differential control of human Treg and effector T cells in tumor immunity by Fe-engineered anti-CTLA-4 antibody. *PNAS* 116:609–18

Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* 144:646–74

Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 299:1057–61

Howie D, Cobbold SP, Adams E, Ten Bokum A, Necula AS, et al. 2017. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. *JCI Insights* 2:e89160

Hoy AJ, Balaban S, Saunders DN. 2017. Adipocyte-tumor cell metabolic crosstalk in breast cancer. *Trends Mol. Med.* 23:381–92

Hui E, Cheung J, Zhu J, Su X, Taylor MJ, et al. 2017. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. *Science* 355:1428–33

Huss DJ, Pellerin AF, Collette BP, Kannan AK, Peng L, et al. 2016. Anti-CD25 monoclonal antibody Fc variants differentially impact Treg cells and immune homeostasis. *Immunology* 148:276–86
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *PNAS* 99:12293–97

Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, et al. 2010. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. *Clin. Cancer Res.* 16:5067–78

Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of differentiation and function. *Annu. Rev. Immunol.* 30:531–64

Josefowicz SZ, Rudensky A. 2009. Control of regulatory T cell lineage commitment and maintenance. *Immunity* 30:616–25

Kalliolias GD, Ivashkiv LB. 2016. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. *Nat. Rev. Rheumatol.* 12(1):49–62

Khattri R, Cox T, Yasayko SA, Ramsdell F. 2003. An essential role for Scurfin in CD4⁺CD25⁺ T regulatory cells. *Nat. Immunol.* 4:337–42

Kim IK, Kim BS, Koh CH, Seok JW, Park JS, et al. 2015. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. *Nat. Med.* 21:1010–17

Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat. Immunol.* 8:191–97

Kleinfeld AM, Okada C. 2005. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing. *J. Lipid Res.* 46:1983–90

Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, et al. 2009. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity. *J. Exp. Med.* 206:2079–89

Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, et al. 2015. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. *Sci. Signal* 8:ra97

Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. 2005. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3⁺CD4⁺CD25⁺ regulatory T cells. *J. Exp. Med.* 202:885–91

Komatsu N, Hori S. 2007. Full restoration of peripheral Foxp3⁺ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. *PNAS* 104:8959–64

Kurose K, Ohue Y, Wada H, Iida S, Ishida T, et al. 2015. Phase Ia study of Foxp3⁺CD4⁺CD25⁺ regulatory T cells in cancer patients. *Blood* 116:210–17

Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, et al. 2017. A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy that is further enhanced in combination with an OX40 agonist. *Clin. Cancer Res.* 23:3416–27

Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. 2010. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4⁺ and CD8⁺ T cells. *Blood* 116:210–17

Liang B, Workman C, Lee J, Chew C, Dale BM, et al. 2008. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. *J. Immunol.* 180:5916–26

Liu X, Mo W, Ye J, Li L, Zhang Y, et al. 2018. Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition. *Nat. Commun.* 9:249

Lochner M, Berod L, Sparwasser T. 2015. Fatty acid metabolism in the regulation of T cell function. *Trends Immunol.* 36:81–91

Lutsiak ME, Semmani RT, De Pascalis R, Kashmiri SV, Schlom J, Sahzevari H. 2005. Inhibition of CD4⁺25⁺ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood* 105:2862–68

Ma C, Kesavarala AH, Eggert T, Medina-Echeverz J, Kleiner DE, et al. 2016. NAFLD causes selective CD4⁺ T lymphocyte loss and promotes hepatocarcinogenesis. *Nature* 531:253–57
Magnuson AM, Kiner E, Ergun A, Park JS, Asinovski N, et al. 2018. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. *PNAS* 115:E10672–81

Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, et al. 2014. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. *Nat. Immunol.* 15:473–81

Mahne AE, Mauze S, Joyce-Shaikh B, Xia J, Bowman EP, et al. 2017. Dual roles for regulatory T-cell depletion and costimulatory signaling in agonistic GITR targeting for tumor immunotherapy. *Cancer Res.* 77:1108–18

Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, et al. 2007. Depletion of CD4⁺CD25⁺ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. *Int. J. Cancer* 120:2723–33

Maj T, Wang W, Crespo J, Zhang H, Wang W, et al. 2017. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. *Nat. Immunol.* 18:1332–41

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, et al. 2013. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. *J. Clin. Investig.* 123:2447–63

Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, et al. 2016. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. *Clin. Cancer Res.* 22:2908–18

McHugh RS, Shevach EM. 2002. Cutting edge: depletion of CD4⁺CD25⁺ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. *J. Immunol.* 168:5979–83

McIntire KR, Sell S, Miller JF. 1964. Pathogenesis of the post-neonatal thymectomy wasting syndrome. *Nature* 204:151–55

Munn DH, Mellor AL. 2016. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. *Trends Immunol.* 37:193–207

Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, et al. 2017. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. *Cancer Immunol. Res.* 5:992–1004

Nagarsheth N, Wicha MS, Zou W. 2017. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. *Nat. Rev. Immunol.* 17(9):559–72

Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, et al. 2001. Human CD4⁺CD25⁺ cells: a naturally occurring population of regulatory T cells. *Blood* 98:2736–44

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity* 11:141–51

Nishizuka Y, Sakakura T. 1969. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. *Science* 166:753–55

Olsen E, Duvc M, Frankel A, Kim Y, Martin A, et al. 2001. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J. Clin. Oncol.* 19:376–88

Onda M, Kobayashi K, Pastan I. 2009. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8⁺ T cell-mediated systemic antitumor immunity. *PNAS* 116(10):4753–82

Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, et al. 2018. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. *PNAS* 115:E6546–55

Pandiyam P, Zheng L, Ishihara S, Reed J, Lenardo MJ. 2007. CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. *Nat. Immunol.* 8:1353–62

Paterson AM, Lovitch SB, Sage PT, Junega VR, Lee Y, et al. 2015. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. *J. Exp. Med.* 212:1603–21

Pearce EL, Poffenberger MC, Chang CH, Jones RG. 2013. Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342:1242454

Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J. Exp. Med.* 206:1717–25
Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, et al. 2011. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 118:4853–62

Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, et al. 2006. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866–72

Piconese S, Valzasina B, Colombo MP. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205:825–39

Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, et al. 2016. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45:1122–34

Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, et al. 2006. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866–72

Piconese S, Valzasina B, Colombo MP. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205:825–39

Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, et al. 2016. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45:1122–34

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, et al. 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600–3

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, et al. 2012. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4:134ra62

Ren L, Yu Y, Wang L, Zhu Z, Lu R, Yao Z. 2016. Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. Oncotarget 7:75763–73

Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, et al. 2016. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 17:1599–611

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl. J. Med. 364:2517–26

Rohrig F, Schulze A. 2016. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16:732–49

Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H. 1977. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 145:455–59

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, et al. 2015. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. PNAS 112:6140–45

Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, et al. 2008. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546–58

Rudensky AY. 2011. Regulatory T cells and Foxp3. Immunol. Rev. 241:260–68

Sage PT, Francisco LM, Carman CV, Sharpe AH. 2013. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat. Immunol. 14:152–61

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, et al. 2016. Two FOXP3+ CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22:679–84

Sakaguchi S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531–62

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151–64

Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, et al. 2019. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor cell exhaustion. Nat. Immunol. 20:724–35

Schaeper U, Murphy JT, Wolchok JD. 2012. Modulation of GITR for cancer immunotherapy. Curr. Opin. Immunol. 24:217–24

Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, et al. 2017. Effect of modified vaccinia Ankara-5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: a randomized clinical trial. JAMA Oncol. 3:e172579

Setoguchi R, Hori S, Takahashi T, Sakaguchi S. 2005. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723–35

Svko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, et al. 2013. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J. Investig. Dermatol. 133:1610–19
Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, et al. 2009. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102–11
Sharma MD, Shinde R, McGaha TL, Huang L, Holmgard RB, et al. 2015. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci. Adv. 1:e1500845
Shen Z, Zhou S, Wang Y, Li RL, Zhong C, et al. 2010. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 136:1585–95
Shimizu J, Yamazaki S, Sakaguchi S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211–18
Shirimali RK, Ahnad S, Verma V, Zeng P, Ananth S, et al. 2017. Concurrent PD-1 blockade negates the effects ofOX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol. Res. 5:755–66
Siu LL, Steeghs N, Meniwen S, Joerger M, Spratlin JL, et al. 2017. Preliminary results of a phase I/IIa study ofBMS-986156 (glucocorticoid-induced tumor necrosis factor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. J. Clin. Oncol. 35:104
Tan W, Zhang W, Srinasra A, Grivennnikov S, Cheng JQ, et al. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature 470:548–53
Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, et al. 2014. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLOS ONE 9:e87705
Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, et al. 2017. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci. Signal. 10:eaa8608
Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, et al. 2007. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. PNAS 104:20884–89
Vignali DA, Collison LW, Workman CJ. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8(7):523–32
Villarreal DO, L’Huilier A, Armington S, Mottershead C, Filippova EV, et al. 2018. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res. 78:5340–48
von Boehmer H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6:338–44
Walker MR, Kaspprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, et al. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J. Clin. Investig. 112:1437–43
Ward ST, Li KK, Hepburn E, Weston CJ, Curibishley SM, et al. 2015. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br. J. Cancer 112:319–28
Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:18–20
Willingham SB, Ho PY, Hotson A, Hill C, Piccione EC, et al. 2018. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti–PD-(L)1 and anti–CTLA-4 in preclinical models. Cancer Immunol. Res. 6:1136–49
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–75
Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, et al. 2018. Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy. J. Thorac. Oncol. 13:521–32
Zheng Y, Josepowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. 2010. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463(7282):808–12
Zhou G, Levitsky HI. 2007. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178:2155–62
Zou W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6:295–307
Contents

AMP-Activated Protein Kinase: Friend or Foe in Cancer?
Diana Vara-Ciruelos, Madhumita Dandapani, and D. Grahame Hardie ..................... 1

Metabolism in the Tumor Microenvironment
Allison N. Lau and Matthew G. Vander Heiden .................................................. 17

Mitophagy and Mitochondrial Dysfunction in Cancer
Kay F. Madeo ......................................................................................................... 41

Targeting MYC Proteins for Tumor Therapy
Elmar Wolf and Martin Eilers .................................................................................. 61

Metabolic Drivers in Hereditary Cancer Syndromes
Marco Sciacovelli, Christina Schmidt, Eamonn R. Maher, and Christian Frezza ........ 77

Investigating Tumor Heterogeneity in Mouse Models
Tuomas Tammela and Julien Sage ........................................................................... 99

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology
Joseph H. Choe, Jasper Z. Williams, and Wendell A. Lim ......................................... 121

Lactate and Acidity in the Cancer Microenvironment
Scott K. Parks, Wolfgang Mueller-Klieser, and Jacques Pouysségur .......................... 141

Reactivation of Endogenous Retroelements in Cancer Development and Therapy
Charles A. Ishak and Daniel D. De Carvalho ........................................................... 159

WNT and β-Catenin in Cancer: Genes and Therapy
Rene Jackstadt, Michael Charles Hodder, and Owen James Sansom .......................... 177

The Epithelial-to-Mesenchymal Transition in Development and Cancer
Alexandre Francou and Kathryn V. Anderson ......................................................... 197

RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications
Huilin Huang, Hengyou Weng, Xiaolan Deng, and Jianjun Chen .............................. 221
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Benoit J. Van den Eynde, Nicolas van Baren, and Jean-François Baurain ............... 241

Deregulation of Chromosome Segregation and Cancer

Natalie L. Curtis, Gian Filippo Ruda, Paul Brennan, and Victor M. Bolanos-Garcia ................................................................. 257

Acquired Resistance in Lung Cancer

Asmin Tulpule and Trever G. Bivona ................................................................. 279

Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy

Gemma L. Kelly and Andreas Strasser ................................................................. 299

Nongenetic Mechanisms of Drug Resistance in Melanoma

Vito W. Rebecca and Meenhard Herlyn ................................................................. 315

Biomarkers for Response to Immune Checkpoint Blockade

Shridar Ganesan and Janice Mehnert ................................................................. 331

Immune-Based Approaches for the Treatment of Pediatric Malignancies

Kristopher R. Bosse, Robbie G. Majzner, Crystal L. Mackall, and John M. Maris ................................................................. 353

The Neural Regulation of Cancer

Shawn Gillespie and Michelle Monje ................................................................. 371

Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression

Anup K. Biswas and Swarnali Acharyya ................................................................. 391

The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer

Warren L. Wu and Thales Papagiannakopoulos ................................................................. 413

The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications

Yichen Xu and Davide Ruggero ................................................................. 437

Regulatory T Cells in Cancer

George Plitas and Alexander Y. Rudensky ................................................................. 459

Errata

An online log of corrections to Annual Review of Cancer Biology articles may be found at http://www.annualreviews.org/errata/cancerbio